within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BX01_Ipriflavone;

model Ipriflavone
  extends Pharmacolibrary.Drugs.ATC.M.M05BX01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M05BX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ipriflavone is a synthetic isoflavone derivative previously investigated for the treatment and prevention of osteoporosis and bone loss. It acts by inhibiting bone resorption and stimulating bone formation. The drug is not currently approved for therapeutic use in the USA or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects after oral administration, based on published reviews and available limited pharmacokinetic studies.</p><h4>References</h4><ol><li><p>Kim, SH, &amp; Lee, MG (2002). Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects. <i>Life sciences</i> 70(11) 1299–1315. DOI:<a href=&quot;https://doi.org/10.1016/s0024-3205(01)01508-9&quot;>10.1016/s0024-3205(01)01508-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11883708/&quot;>https://pubmed.ncbi.nlm.nih.gov/11883708</a></p></li><li><p>Lee, DY, et al., &amp; Lee, MG (2009). Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 38(5) 465–471. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2009.09.008&quot;>10.1016/j.ejps.2009.09.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19761842/&quot;>https://pubmed.ncbi.nlm.nih.gov/19761842</a></p></li><li><p>Chung, HJ, et al., &amp; Lee, MG (2008). Effects of E. Coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11. <i>Journal of pharmaceutical sciences</i> 97(11) 5024–5036. DOI:<a href=&quot;https://doi.org/10.1002/jps.21343&quot;>10.1002/jps.21343</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18314883/&quot;>https://pubmed.ncbi.nlm.nih.gov/18314883</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ipriflavone;
